Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ascendis Pharma A/S ASND

Healthcare Biotechnology
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis... see more

Recent & Breaking News (NDAQ:ASND)

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

GlobeNewswire 6 days ago

FDA Accepts TransCon® CNP NDA for Priority Review

GlobeNewswire 13 days ago

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

GlobeNewswire May 13, 2025

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

GlobeNewswire May 12, 2025

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

GlobeNewswire May 5, 2025

Ascendis Pharma Reports First Quarter 2025 Financial Results

GlobeNewswire May 1, 2025

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

GlobeNewswire April 24, 2025

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

GlobeNewswire March 31, 2025

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 24, 2025

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

GlobeNewswire February 12, 2025

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire February 12, 2025

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

GlobeNewswire February 5, 2025

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 12, 2025

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2025

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

GlobeNewswire December 19, 2024

New InsiGHTS Trial of TransCon(TM) hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

GlobeNewswire December 16, 2024

FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon(TM) hGH for the Treatment of Adults with Growth Hormone Deficiency

GlobeNewswire December 12, 2024

Ascendis Pharma Reports Third Quarter 2024 Financial Results

GlobeNewswire November 14, 2024

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

GlobeNewswire November 7, 2024

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

GlobeNewswire November 4, 2024